Subscribe to RSS
DOI: 10.1055/s-0035-1561465
The Rakicidin Family of Anticancer Natural Products – Synthetic Strategies towards a New Class of Hypoxia-Selective Cytotoxins
Publication History
Received: 09 April 2016
Accepted after revision: 09 May 2016
Publication Date:
01 June 2016 (online)
Abstract
Rakicidin A is a prominent member of a small class of macrocyclic lipodepsipeptide natural products that contain an electrophilic 4-amido-2,4-pentadienoate (APD) functionality. Rakicidin A displays selective growth inhibitory activity against hypoxic cancer cells as well as imatinib-resistant chronic myelogenous leukemia (CML) cells. In this paper we present and discuss the two known synthetic routes to rakicidin A, which provide an instructive comparison of strategies used to address the synthetic challenges inherent to rakicidin A. In addition to the synthetic discussion we provide a status on the ongoing biological investigations and emerging structure–activity relationships of the rakicidin scaffold.
1 Introduction
2 The APD-CLD Class of Natural Products
3 Total Syntheses of Rakicidin A
4 Biological Investigations of Rakicidin A and Analogues
5 Conclusion and Perspectives
-
References
- 1 Current address: Department of Chemistry, McGill University, 801 Sherbrooke Street West, Room 300, Montreal, Quebec, H3A 0B8, Canada.
- 2 Newman DJ, Cragg GM. J. Nat. Prod. 2016; 79: 629
- 3 Li JW.-H, Vederas JC. Science 2009; 325: 161
- 4 Shen B. Cell 2015; 163: 1297
- 5 Carlson EE. ACS Chem. Biol. 2010; 5: 639
- 6 McBrien KD, Berry RL, Lowe SE, Neddermann KM, Bursuker I, Huang S, Klohr SE, Leet JE. J. Antibiot. 1995; 48: 1446
- 7 Nishioka H, Nakajima S, Nagashima M, Kojiri K, Suda H. JP 10147594 A, 1998 19980602
- 8 Igarashi M, Shida T, Sasaki Y, Kinoshita N, Naganawa H, Hamada M, Takeuchi T. J. Antibiot. 1999; 52: 873
- 9 Hu J.-F, Wunderlich D, Sattler I, Feng X.-Z, Grabley S, Thiericke R. Eur. J. Org. Chem. 2000; 3353
- 10 Igarashi Y, Shimasaki R, Miyanaga S, Oku N, Onaka H, Sakurai H, Saiki I, Kitani S, Nihira T, Wimonsiravude W, Panbangred W. J. Antibiot. 2010; 63: 563
- 11 Carr G, Poulsen M, Klassen JL, Hou Y, Wyche TP, Bugni TS, Currie CR, Clardy J. Org. Lett. 2012; 14: 2822
- 12 Oku N, Matoba S, Yamazaki YM, Shimasaki R, Miyanaga S, Igarashi Y. J. Nat. Prod. 2014; 77: 2561
- 13 Yamazaki Y, Kunimoto S, Ikeda D. Biol. Pharm. Bull. 2007; 30: 261
- 14 Takeuchi M, Ashihara E, Yamazaki Y, Kimura S, Nakagawa Y, Tanaka R, Yao H, Nagao R, Hayashi Y, Hirai H, Maekawa T. Cancer Sci. 2011; 102: 591
- 15 Sang F, Li D, Sun X, Cao X, Wang L, Sun J, Sun B, Wu L, Yang G, Chu X, Wang J, Dong C, Geng Y, Jiang H, Long H, Chen S, Wang G, Zhang S, Zhang Q, Chen Y. J. Am. Chem. Soc. 2014; 136: 15787
- 16 Tsakos M, Clement LL, Schaffert ES, Olsen FN, Rupiani S, Djurhuus R, Yu W, Jacobsen KM, Villadsen NL, Poulsen TB. Angew. Chem. Int. Ed. 2016; 55: 1030
- 17a Sang F, Ding Y, Wang J, Sun B, Sun J, Geng Y, Zhang Z, Ding K, Wu L.-L, Liu J.-W, Bai C, Yang G, Zhang Q, Li L.-Y, Chen Y. J. Med. Chem. 2016; 59: 1184
- 17b Yang Z, Yang G, Ma M, Li J, Liu J, Wang J, Jiang S, Zhang Q, Chen Y. Org. Lett. 2015; 17: 5725
- 18 Poulsen TB. Chem. Commun. 2011; 47: 12837
- 19 Clement LL, Tsakos M, Schaffert ES, Scavenius C, Enghild JJ, Poulsen TB. Chem. Commun. 2015; 51: 12427
- 20 Olsen FN, Tsakos M, Poulsen TB. Synlett 2015; 26: 2697
- 21a Oku N, Matoba S, Yamazaki YM, Shimasaki R, Miyanaga S, Igarashi Y. J. Nat. Prod. 2014; 77: 2561
- 21b Oku N, Matoba S, Yamazaki YM, Shimasaki R, Miyanaga S, Igarashi Y. J. Nat. Prod. 2015; 78: 969
- 22 Tsakos M, Schaffert ES, Clement LL, Villadsen NL, Poulsen TB. Nat. Prod. Rep. 2015; 32: 605
- 23a Vaupel P, Mayer A. Cancer Metastasis Rev. 2007; 26: 225
- 23b Rankin EB, Giaccia AJ. Science 2016; 352: 175
- 24 Peng G, Liu Y. Trends Pharmacol. Sci. 2015; 36: 374
- 25 Pattabiraman DR, Weinberg RA. Nat. Rev. Drug Discovery 2014; 13: 497
See also: